The modular platform not only targets solid tumors but could also enhance traditional autologous and in vivo T cell therapies
This partnership has led to a 10% boost in delivery speed
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Combination creates a leading, next generation claims operating system for payers, with end-to-end AI capabilities for claims, payments, care & utilization management, payment integrity, and member engagement, serving 115+ health plans
The study showed a significant 29% reduction in the risk for heart attack, stroke and death from any cause in the Wegovy users
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies.
Subscribe To Our Newsletter & Stay Updated
